CTLA4 and hepatocellular carcinoma: Besides, a phase III trial evaluating the efficacy and safety of IBI310 (CTLA-4 inhibitor) plus sintilimab (PD-1 inhibitor) versus sorafenib as first-line treatment for advanced HCC is currently recruiting (NCT04720716, Table 3).